{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:47:31Z","timestamp":1792450051576,"version":"4.5.0"},"reference-count":18,"publisher":"Siapec Servizi Srl","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-n1281","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T15:06:36Z","timestamp":1763391996000},"page":"366-373","source":"Crossref","is-referenced-by-count":1,"title":["Current approaches, barriers, and future directions in pleural mesothelioma diagnostics: results from an Italian National Survey"],"prefix":"10.32074","volume":"117","author":[{"given":"Federica","family":"Pezzuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barbisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pelosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Papotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisella","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2025,10]]},"reference":[{"key":"10.32074\/1591-951X-N1281_ref1","unstructured":"WHO Classification of Tumours Editorial Board. (2021). Thoracic tumours (5th ed.). International Agency for Research on Cancer. Published online 2021."},{"key":"10.32074\/1591-951X-N1281_ref2","doi-asserted-by":"crossref","unstructured":"Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2022;33(2):129-142. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"10.32074\/1591-951X-N1281_ref3","doi-asserted-by":"crossref","unstructured":"Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology. 2022;33(5):488-499. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.074","DOI":"10.1016\/j.annonc.2022.01.074"},{"key":"10.32074\/1591-951X-N1281_ref4","doi-asserted-by":"crossref","unstructured":"Calabr\u00f2 L, Bronte G, Grosso F, et al. Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1333661","DOI":"10.3389\/fimmu.2023.1333661"},{"key":"10.32074\/1591-951X-N1281_ref5","doi-asserted-by":"crossref","unstructured":"Pezzuto F, Lunardi F, Vedovelli L, et al. P14\/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.653497","DOI":"10.3389\/fonc.2021.653497"},{"key":"10.32074\/1591-951X-N1281_ref6","doi-asserted-by":"crossref","unstructured":"Mannarino L, Paracchini L, Pezzuto F, et al. Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. Int J Mol Sci. 2022;23(10):5786. https:\/\/doi.org\/10.3390\/ijms23105786","DOI":"10.3390\/ijms23105786"},{"key":"10.32074\/1591-951X-N1281_ref7","unstructured":"Fortarezza F, Pezzuto F, Maniglio S, et al. Adverse Prognostic Impact of Transitional and Pleomorphic Patterns in Pleural Nonepithelioid Mesothelioma Insights From Comprehensive Analysis and Reticulin Stain. https:\/\/doi.org\/10.5858\/arpa.2023-0523"},{"key":"10.32074\/1591-951X-N1281_ref8","doi-asserted-by":"crossref","unstructured":"Rossi G, Righi L, Barbisan F, et al. BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report. J Pers Med. 2024;14(4):394. https:\/\/doi.org\/10.3390\/jpm14040394","DOI":"10.3390\/jpm14040394"},{"key":"10.32074\/1591-951X-N1281_ref9","doi-asserted-by":"crossref","unstructured":"Husain AN, Chapel DB, Attanoos R, et al. Guidelines for Pathologic Diagnosis of Mesothelioma. Arch Pathol Lab Med. Published online November 1, 2024. https:\/\/doi.org\/10.5858\/arpa.2023-0304-ra","DOI":"10.1201\/9781003431909-11"},{"key":"10.32074\/1591-951X-N1281_ref10","doi-asserted-by":"crossref","unstructured":"Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Modern Pathology. 2015;28(8):1043-1057. https:\/\/doi.org\/10.1038\/modpathol.2015.65","DOI":"10.1038\/modpathol.2015.65"},{"key":"10.32074\/1591-951X-N1281_ref11","doi-asserted-by":"crossref","unstructured":"Righi L, Duregon E, Vatrano S, et al. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study. Journal of Thoracic Oncology. 2016;11(11):2006-2017. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.020","DOI":"10.1016\/j.jtho.2016.06.020"},{"key":"10.32074\/1591-951X-N1281_ref12","unstructured":"Pleural Specimens Tumour Size (Note 5) Mm maximum thickness of any mass Indeterminate dimensions of dominant mass Peritoneal Specimens dimensions of dominant mass dimensions of largest nodule and or Low Grade (Nuclear Grades I and II without Necrosis) High Grade (Nuclear Grade II with Necrosis, Nuclear Grade III with or without Necrosis).; 2022."},{"key":"10.32074\/1591-951X-N1281_ref13","doi-asserted-by":"crossref","unstructured":"Shiffman RN, Shekelle P, Overhage J Marc, et al. Standardized Reporting of Clinical Practice Guidelines: A Proposal from the Conference on Guideline Standardization*. Vol 139.; 2003. www.annals.org","DOI":"10.7326\/0003-4819-139-6-200309160-00013"},{"key":"10.32074\/1591-951X-N1281_ref14","doi-asserted-by":"crossref","unstructured":"Swillens JEM, Sluijter CE, Overbeek LIH, et al. Identification of barriers and facilitators in nationwide implementation of standardized structured reporting in pathology: a mixed method study. Virchows Archiv. 2019;475(5):551-561. https:\/\/doi.org\/10.1007\/s00428-019-02609-6","DOI":"10.1007\/s00428-019-02609-6"},{"key":"10.32074\/1591-951X-N1281_ref15","doi-asserted-by":"crossref","unstructured":"Febres-Aldana CA, Chang JC, Jungbluth AA, et al. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma. Modern Pathology. 2024;37(3). https:\/\/doi.org\/10.1016\/j.modpat.2023.100420","DOI":"10.1016\/j.modpat.2023.100420"},{"key":"10.32074\/1591-951X-N1281_ref16","doi-asserted-by":"crossref","unstructured":"Chapel DB, Schulte JJ, Berg K, et al. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Modern Pathology. 2020;33(2):245-254. https:\/\/doi.org\/10.1038\/s41379-019-0310-0","DOI":"10.1038\/s41379-019-0310-0"},{"key":"10.32074\/1591-951X-N1281_ref17","doi-asserted-by":"crossref","unstructured":"Chung CTS, Santos GDC, Hwang DM, et al. FISH assay development for the detection of p16\/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63(7):630-634. https:\/\/doi.org\/10.1136\/jcp.2010.076794","DOI":"10.1136\/jcp.2010.076794"},{"key":"10.32074\/1591-951X-N1281_ref18","doi-asserted-by":"crossref","unstructured":"Annaratone L, De Palma G, Bonizzi G, et al. Basic principles of biobanking: from biological samples to precision medicine for patients. Virchows Archiv. 2021;479(2):233-246. https:\/\/doi.org\/10.1007\/s00428-021-03151-0","DOI":"10.1007\/s00428-021-03151-0"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/1281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T15:07:10Z","timestamp":1763392030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pathologica.it\/article\/view\/1281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-n1281","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"7"}}